{"id":"W1971365073","doi":"10.2147/btt.s6748","title":"Everolimus: the first approved product for patients with advanced renal cell cancer after sunitinib and/or sorafenib","year":2010,"lang":"en","type":"article","venue":"Biologics","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Sunitinib; Sorafenib; Everolimus; Medicine; Internal medicine; Oncology; Renal cell carcinoma; Urology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004072177,0.0002240828,0.0005140542,0.0002957842,0.000277802,0.0006586629,0.0001745773,0.0005534695,0.01070655],"category_scores_gemma":[0.0004988829,0.00007906555,0.0005188539,0.0002618533,0.0001174813,0.0002602869,0.000188977,0.0007765276,0.00244647],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000466808,"about_ca_system_score_gemma":0.0006008312,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005464824,"about_ca_topic_score_gemma":0.002207282,"domain_scores_codex":[0.9997628,0.00004082876,0.0000173612,0.00002253747,0.0001154256,0.00004104916],"domain_scores_gemma":[0.9996964,0.00003513094,0.00008725828,0.00001066353,0.00005131783,0.0001193031],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.01047239,0.0008059632,0.01011408,0.001660588,0.0003895446,0.001337575,0.0001071136,0.0001842455,0.02333361,0.0008748322,0.111453,0.839267],"study_design_scores_gemma":[0.01157319,0.01195855,0.1036926,0.0004881879,0.0007956543,0.01041414,0.00008533458,0.0006086169,0.01961354,0.0004450847,0.8402644,0.00006066943],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.5085087,0.3516307,0.002371207,0.01469239,0.00378466,0.001075013,0.004633348,0.0009628576,0.112341],"genre_scores_gemma":[0.8327413,0.07301681,0.003069013,0.006156009,0.002442176,0.0003260453,0.005016895,0.0001308541,0.07710099],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01070655,"threshold_uncertainty_score":0.03581697,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01719074779736497,"score_gpt":0.2452960122209289,"score_spread":0.228105264423564,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}